Mental health conditions

FDA gives the green light for cariprazine to treat schizophrenia or bipolar disorder

The US Food and Drug Administration (pictured) has approved the atypical antipsychotic cariprazine (Vraylar) to treat adults with schizophrenia or bipolar disorder

Source: Wikimedia Commons

The Food and Drug Administration has approved cariprazine (Vraylar) to treat adults with schizophrenia or bipolar disorder

The US Food and Drug Administration has approved the atypical antipsychotic cariprazine (Vraylar) to treat adults with schizophrenia or bipolar disorder. 

Vraylar, an oral, once daily antipsychotic, is approved for the acute treatment of adult patients with manic or mixed episodes associated with bipolar I disorder, with a recommended dose range of 3–6mg/day and for the treatment of schizophrenia in adults, with a recommended dose range of 1.5–6mg per day. 

Common side effects for patients administered cariprazine with schizophrenia included tremor, slurred speech and involuntary muscle movement. For those patients with bipolar, the most common side effects from the drug were the urge to move, indigestion, vomiting, drowsiness and restlessness. 

Although the FDA has approved the product for adults, it has not been given the go ahead for the treatment of older patients with dementia-related psychosis because of an associated risk of death with this group. Cariprazine carries a boxed warning reflecting this restriction. 

Cariprazine does not have a marketing authorisation in the European Union, according to the EU’s medicines safety watchdog the European Medicines Agency (EMA). According to the EMA, the product is not in the process of being approved.

Citation: The Salvadore DOI: 10.1211/PJ.2015.20069435

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Traditional Medicine

    Covers the major traditional medicine systems. Gives information on philosophy, practice, safety, evidence and examples.

    £43.00
  • Non-prescription Medicines

    Reviews over-the-counter medicines, arranged by the conditions they are licensed to treat. Includes product recommendations.

    £38.00
  • Rules and Guidance for Pharmaceutical Distributors 2017 (The Green Guide)

    Essential guidance for distributors of medicines for human use in Europe, compiled by the MHRA.

    £72.00

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete

Supplementary images

  • The US Food and Drug Administration (pictured) has approved the atypical antipsychotic cariprazine (Vraylar) to treat adults with schizophrenia or bipolar disorder

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

levitra without prescription

avanafil kaufen

levitra 20mg